Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alkermes ( (ALKS) ) just unveiled an announcement.
On September 9, 2025, Alkermes Pharma Ireland Limited entered into an agreement with Amneal Pharmaceuticals to distribute an authorized generic version of VIVITROL® in the U.S., contingent on certain launch conditions. Additionally, in August and September 2025, Alkermes filed patent infringement lawsuits against Teva, Apotex, and MSN following their attempts to market generic versions of LYBALVI® before patent expiration, triggering FDA approval stays under the Hatch-Waxman Act.
The most recent analyst rating on (ALKS) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Alkermes stock, see the ALKS Stock Forecast page.
Spark’s Take on ALKS Stock
According to Spark, TipRanks’ AI Analyst, ALKS is a Outperform.
Alkermes’ strong financial performance and positive earnings call are the most significant factors driving the score. The company’s robust cash position and successful clinical trials further enhance its outlook. Technical analysis and valuation are supportive but less impactful.
To see Spark’s full report on ALKS stock, click here.
More about Alkermes
Alkermes is a pharmaceutical company involved in the development and manufacturing of innovative medicines in the field of neuroscience and oncology. The company focuses on creating products that address unmet medical needs and improve patient outcomes.
Average Trading Volume: 1,953,485
Technical Sentiment Signal: Hold
Current Market Cap: $4.57B
For an in-depth examination of ALKS stock, go to TipRanks’ Overview page.